American Journal of Kidney Diseases
Volume 53, Issue 5 , Pages 751-759 , May 2009

Kidney Pathological Changes in Metabolic Syndrome: A Cross-sectional Study

  • Mariam P. Alexander, MD

      Affiliations

    • Renal Division, Brigham and Women's Hospital, Boston, MA
    • Department of Pathology, Brigham and Women's Hospital, Boston, MA
    • Harvard Medical School, Boston, MA
    • ,
  • Tejas V. Patel, MD

      Affiliations

    • Renal Division, Brigham and Women's Hospital, Boston, MA
    • Harvard Medical School, Boston, MA
    • ,
  • Youssef M.K. Farag, MD

      Affiliations

    • Renal Division, Brigham and Women's Hospital, Boston, MA
    • Harvard Medical School, Boston, MA
    • ,
  • Adriana Florez, MD

      Affiliations

    • Department of Pathology, Brigham and Women's Hospital, Boston, MA
    • Harvard Medical School, Boston, MA
    • ,
  • Helmut G. Rennke, MD

      Affiliations

    • Department of Pathology, Brigham and Women's Hospital, Boston, MA
    • Harvard Medical School, Boston, MA
    • ,
  • Ajay K. Singh, MBBS, MBA, FRCP

      Affiliations

    • Renal Division, Brigham and Women's Hospital, Boston, MA
    • Harvard Medical School, Boston, MA
    • Corresponding Author InformationAddress correspondence to Ajay K. Singh, MBBS, MBA, FRCP, Renal Division, Brigham and Women's Hospital, MRB-4, 75 Francis St, Boston, MA 02115

Received 19 August 2008 ,Accepted 5 January 2009.

References 

  1. Reaven GM. Banting lecture 1988 (Role of insulin resistance in human disease). Diabetes. 1988;37:1595–1607
  2. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome—A new worldwide definition. Lancet. 2005;366:1059–1062
  3. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004;27:2444–2449
  4. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: Prevalence in worldwide populations. Endocrinol Metab Clin North Am. 2004;33:351–375table of contents
  5. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence. Diabetes Care. 2005;28:1769–1778
  6. Obunai K, Jani S, Dangas GD. Cardiovascular morbidity and mortality of the metabolic syndrome. Med Clin North Am. 2007;91:1169–1184x
  7. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752
  8. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  9. Resnick HE, Jones K, Ruotolo G, et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: The Strong Heart Study. Diabetes Care. 2003;26:861–867
  10. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722–728
  11. Lin WY, Liu CS, Li TC, et al. In addition to insulin resistance and obesity, hyperuricemia is strongly associated with metabolic syndrome using different definitions in Chinese populations: A population-based study (Taichung Community Health Study). Ann Rheum Dis. 2008;67:432–433
  12. Hollenberg NK. Obesity and the kidney: Why is the kidney at risk?. Kidney Int. 2007;71:187–188
  13. Ritz E. Metabolic syndrome: An emerging threat to renal function. Clin J Am Soc Nephrol. 2007;2:869–871
  14. Rea DJ, Heimbach JK, Grande JP, et al. Glomerular volume and renal histology in obese and non-obese living kidney donors. Kidney Int. 2006;70:1636–1641
  15. Serra A, Romero R, Lopez D, et al. Renal injury in the extremely obese patients with normal renal function. Kidney Int. 2008;73:947–955
  16. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16:2134–2140
  17. Kanauchi M, Kanauchi K, Kimura K, Inoue T, Saito Y. Associations of chronic kidney disease with the metabolic syndrome in non-diabetic elderly. Nephrol Dial Transplant. 2006;21:3608–3609
  18. Ninomiya T, Kiyohara Y. Albuminuria and chronic kidney disease in association with the metabolic syndrome. J Cardiometab Syndr. 2007;2:104–107
  19. Tanaka H, Shiohira Y, Uezu Y, Higa A, Iseki K. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int. 2006;69:369–374
  20. Levey AS, Greene T, Kusek J, Beck G. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000;11:55A;(abstr)
  21. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999;55:713–723
  22. Rasband WS. Image J, 1997-2007 (US National Institutes of Health, Bethesda, MD). http://rsb.info.nih.gov/ij/Accessed June 18, 2008
  23. Weibel ER. Elementary introduction to stereological principles. In:  Wiebel ER editors. Stereological methods (Practical methods for Biological morphometry). London, UK: Academic Press; 1979;p. 44–45
  24. Toprak O, Cirit M, Yesil M, et al. Metabolic syndrome as a risk factor for contrast-induced nephropathy in non-diabetic elderly patients with renal impairment. Kidney Blood Press Res. 2006;29:2–9
  25. Tozawa M, Iseki C, Tokashiki K, et al. Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults. Hypertens Res. 2007;30:937–943
  26. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167–174
  27. Eddy AA. Interstitial fibrosis in hypercholesterolemic rats: Role of oxidation, matrix synthesis, and proteolytic cascades. Kidney Int. 1998;53:1182–1189
  28. Grone HJ, Hohbach J, Grone EF. Modulation of glomerular sclerosis and interstitial fibrosis by native and modified lipoproteins. Kidney Int Suppl. 1996;54:S18–S22
  29. Scheuer H, Gwinner W, Hohbach J, et al. Oxidant stress in hyperlipidemia-induced renal damage. Am J Physiol Renal Physiol. 2000;278:F63–F74
  30. Joles JA, Kunter U, Janssen U, et al. Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. J Am Soc Nephrol. 2000;11:669–683
  31. Dominguez J, Wu P, Packer CS, Temm C, Kelly KJ. Lipotoxic and inflammatory phenotypes in rats with uncontrolled metabolic syndrome and nephropathy. Am J Physiol Renal Physiol. 2007;293:F670–F679
  32. Ziyadeh FN. Mediators of diabetic renal disease: The case for TGF-beta as the major mediator. J Am Soc Nephrol. 2004;15(suppl 1):S55–S57
  33. Singh DK, Winocour P, Farrington K. Mechanisms of disease: The hypoxic tubular hypothesis of diabetic nephropathy. Nat Clin Pract Nephrol. 2008;4:216–226
  34. Ueno M, Kawashima S, Nishi S, et al. Tubulointerstitial lesions in non-insulin dependent diabetes mellitus. Kidney Int Suppl. 1997;63:S191–S194
  35. Al-Aly Z. Medial vascular calcification in diabetes mellitus and chronic kidney disease: The role of inflammation. Cardiovasc Hematol Disord Drug Targets. 2007;7:1–6
  36. Kosugi T, Yuzawa Y, Sato W, et al. Midkine is involved in tubulointerstitial inflammation associated with diabetic nephropathy. Lab Invest. 2007;87:903–913
  37. Sato W, Kadomatsu K, Yuzawa Y, et al. Midkine is involved in neutrophil infiltration into the tubulointerstitium in ischemic renal injury. J Immunol. 2001;167:3463–3469
  38. Kobayashi S, Moriya H, Nakabayashi I, Nishiyama J, Fukuda T. Angiotensin II and IGF-I may interact to regulate tubulointerstitial cell kinetics and phenotypic changes in hypertensive rats. Hypertens Res. 2002;25:257–269
  39. Cao Z, Cooper ME. Role of angiotensin II in tubulointerstitial injury. Semin Nephrol. 2001;21:554–562
  40. Nakagawa T, Kang DH, Ohashi R, et al. Tubulointerstitial disease: Role of ischemia and microvascular disease. Curr Opin Nephrol Hypertens. 2003;12:233–241
  41. Sanchez-Lozada LG, Tapia E, Jimenez A, et al. Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. Am J Physiol Renal Physiol. 2007;292:F423–F429
  42. Nakagawa T, Tuttle KR, Short RA, Johnson RJ. Hypothesis: Fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol. 2005;1:80–86
  43. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67:1739–1742
  44. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: An emerging epidemic. Kidney Int. 2001;59:1498–1509
  45. Nasr SH, D'Agati VD. Nodular glomerulosclerosis in the nondiabetic smoker. J Am Soc Nephrol. 2007;18:2032–2036
  46. Bijol V, Mendez GP, Hurwitz S, Rennke HG, Nose V. Evaluation of the nonneoplastic pathology in tumor nephrectomy specimens: Predicting the risk of progressive renal failure. Am J Surg Pathol. 2006;30:575–584
  47. Brenner BM, Mackenzie HS. Nephron mass as a risk factor for progression of renal disease. Kidney Int Suppl. 1997;63:S124–S127
  48. Patel A, MacMahon S, Chalmers S, et al. ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572
  49. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–591
  50. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet. 2003;361:2005–2016
  51. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol. 2003;14:1605–1613
  52. Thomas MC, Atkins RC. Blood pressure lowering for the prevention and treatment of diabetic kidney disease. Drugs. 2006;66:2213–2234

 Originally published online as doi:10.1053/j.ajkd.2009.01.255 on April 2, 2009.

 M.P.A. and T.V.P. contributed equally to this work.

 Because an author of this manuscript is an editor for AJKD, the peer-review and decision-making processes were handled entirely by an Associate Editor (Rulan Parekh, MD, Johns Hopkins University) who served as Acting Editor-in-Chief. Details of the journal's procedures for potential editor conflicts are given in the Editorial Policies section of the AJKD website.

PII: S0272-6386(09)00392-8

doi: 10.1053/j.ajkd.2009.01.255

American Journal of Kidney Diseases
Volume 53, Issue 5 , Pages 751-759 , May 2009

Article Tools

* Image Usage & Resolution